Resistance in trans-ition

Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854

Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman, The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies Clinical Cancer Research. ,vol. 21, pp. 3924- 3933 ,(2015) , 10.1158/1078-0432.CCR-15-0560

L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003

Dalia Ercan, Hwan Geun Choi, Cai-Hong Yun, Marzia Capelletti, Ting Xie, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne, EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research. ,vol. 21, pp. 3913- 3923 ,(2015) , 10.1158/1078-0432.CCR-14-2789

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely, Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers Clinical Cancer Research. ,vol. 19, pp. 2240- 2247 ,(2013) , 10.1158/1078-0432.CCR-12-2246

Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn SME Theelen, Chee K Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A Papadimitrakopoulou, None, Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer New England Journal of Medicine. ,vol. 376, pp. 629- 640 ,(2017) , 10.1056/NEJMOA1612674

Koichi Akashi, Hiroyuki Sasaki, Yoichi Nakanishi, Noriko Hidaka, Eiji Iwama, Naoki Kubo, Taishi Harada, Kohta Miyawaki, Kentaro Tanaka, Isamu Okamoto, Eishi Baba, Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer. ,vol. 108, pp. 75- 82 ,(2017) , 10.1016/J.LUNGCAN.2017.02.019

Zhen Wang, Jin-Ji Yang, Jie Huang, Jun-Yi Ye, Xu-Chao Zhang, Hai-Yan Tu, Han Han-Zhang, Yi-Long Wu, Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance Journal of Thoracic Oncology. ,vol. 12, pp. 1723- 1727 ,(2017) , 10.1016/J.JTHO.2017.06.017

Suresh S Ramalingam, James C-H Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J Carl Barrett, Kenneth S Thress, Pasi A Jänne, None, Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 36, pp. 841- 849 ,(2018) , 10.1200/JCO.2017.74.7576

Surein Arulananda, Hongdo Do, Ashan Musafer, Paul Mitchell, Alexander Dobrovic, Thomas John, Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. ,vol. 12, pp. 1728- 1732 ,(2017) , 10.1016/J.JTHO.2017.08.006